卵巢癌中C-kit、C-abl、PDGFRα的表达及意义

The Expression and Clinical Significance of C-kit、C-abl and PDGFRα in Ovarian Carcinoma

目的探讨酪氨酸激酶受体在卵巢癌中的表达及意义。方法应用免疫组化SP方法,检测20例正常卵巢组织和60例卵巢癌中酪氨酸激酶受体C-kit、C-abl和PDGFRα的表达。结果至少含一种酪氨酸激酶受体的阳性率为79%;C-kit、C-abl和PDGFRα在卵巢癌中阳性表达率分别为58.3%,70%,73.3%,其中C-kit和PDGFRα蛋白的阳性表达率较高,明显高于正常卵巢组织,差异有显著性(P<0.01)。C-abl在卵巢癌中表达高于正常卵巢组织,差异无显著性。结论C-kit和PDGFRα与卵巢癌的发生和发展密切相关,应用酪氨酸激酶抑制剂治疗有可能性。

Objective This study was to examine the expression of tyrosine kinase receptor（TKRs） C - kit , C - abl and PDGFRα, in ovary carcinoma. Methods The expression of C - kit ,C - abl and PDGFRα in tumor tissue of 60 specimens of ovary carcinoma and normal fissue of 20 specimens of overy was examined by immunohistochemistry SP method. Results Immunoreactivity was detected in 79% of the tumor to at least one TKR. The total positive expression rate of C - kit ,C - abl and PDGFRα in ovary carcinoma was 58.3% , 70% ,73.3% ,respectively. The positive expression rate of C - kit and PDGFRα is significantly higher in tumor tissues than in normal tissues （P 〈 0. 01 ）. The positive expression rate of C -abl is higher in tumor tissues than in normal tissues ,but this did not achieve statistical significance. The positive expression rate of C - kit and PDGFRα in ovary carcinoma was statistically correlated with the differentiated grade group and FIGO clinical stages. Conclusions C - kit 和 PDGFRαplay an important role in ovarian carcinoma, suggesting the potential usefulness of tyrosine kinase receptor inhibitor in the treatment of ovarian carcinoma.